BETHESDA, Md., Sept. 23 -- The U.S. Department of Health & Human Services' National Institutes of Health issued the following press release:
A new National Institutes of Health (NIH)-funded study indicates that the experimental drug kamuvudine-9 (K-9) facilitates recovery from pre-existing vision loss and paralysis in animal models of multiple sclerosis (MS). Researchers at the University of Virginia found that these benefits were likely the result of K-9 preventing the inflammasome, a cell-killing alarm system native to the brain and spinal cord, from activating. A nationwide analysis of more than 3 million patients showed reduced rates of MS and MS relapses among those receiving common antiviral medications called NRTIs, of which K-9 is ...